SERVICES
Great bonds make Great Proteins.
Integrated services to ____ your molecule from gene ________ to potential drug candidate. ______ multiple host systems - _________, yeast and mammalian.
Process Development
Process development at ______ covers a significant broad ________ of R&D activities coupled ____ various input parameters based __ in silico analysis, real-world ________ and analytical data. Process ___________ initiates with significant clone ___________ strategies; which then is _____________ scaled up from shake ______, to small scale bioreactors (0.5-2.0_) and subsequently into 5L-50L-500L-1100L __________.
Our upstream process ___________ group develops high cell _______ E. coli batch, fed-batch ___ semi-continuous processes for therapeutic ___________ proteins. This group interacts ____ the strategy and clone ___________ groups from the initiation __ the project. This allows ___ the final objective to _______ evident and visible to ___ PD group and subsequent __________ and manufacturing groups. COGS, ___ process simplicity is one __ our target hallmarks of _______ with Premas.
Monoclonal antibodies and _________ derived proteins, produced from _________ cell cultures are process _________ with similar thoughts. Our ________ is flexible, partnership based _______ our clients’ needs. ____ bioreactors (5-25L) and Single ___ (1-10L) constitute the first ____ of process development and _______ up. Gram level yields __ the clone /shake flask ______ are enhanced with media ___________, optimizing feed strategies, upstream _______ development and multi-parametric inputs ___ controls.
Our downstream process ___________ team has delivered over >650 proteins, of which about 100’_ of them have ____ scale up to > 100_ culture volumes. With unit __________ scalable to 1000’s of _____ of product, harvesting and _____________ steps have significant capacities, __________, and access to multiple _______, e.g. high speed continuous ___________, concentrations and diafiltrations systems (1000’_ of Liters), both cassette ___ hollow fiber based systems.
Chromatography systems and ______ defined process protocols exist __ Premas. With the vast __________ of over 14 years, ______ has developed unique scale ____ models (ml to 100’sof _) and processes to rapidly ________ on possible steps, yields ___ outcomes. (Reference: Application Note: ____ to Phase 1 material __ 10 months). Use of _____-_____ components and analysis, Premas ___ been able to deliver ____ of the significantly challenging ________ and processes at low ____.
Further downstream process ___________ is possible at Premas _____ we develop high protein _____________ formulations and lyophilization cycles. ______ has both small and _____ scale development lyophilizers.
